WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Sunday, December 3, 2023 
Add Press Release News | News Feeds Feeds | Email This News Email


Severe Asthma Digital Marketing Trends Report 2022 Featuring Sanofi, Regeneron, Genentech, Novartis, GSK, AstraZeneca, Amgen, & Teva
Tuesday, November 29, 2022

DUBLIN, Nov. 21, 2022 /PRNewswire/ -- The "Digital Marketing Trends in Severe Asthma" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Sanofi/Regeneron's Dupixent.com achieved the highest traffic across branded severe asthma patient sites in the US from July 2021 to June 2022, with about 7,800,000 visits, followed by Novartis' Xolair.com, and GSK's Nucala.com.

The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca's Tezspire.com had the highest amount of direct traffic (83%), while remaining brands, Dupixent, Cinqair, Nucala, and Xolair, had levels between 52-66%.

For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000. Dupixent.com was supported by the most paid keywords at approximately 10,650 keywords, followed by Tezspire.com at about 5,800 keywords.

For branded HCP sites in the US, Sanofi/Regeneron's Dupixenthcp.com had the highest number of visits at approximately 775,000 total visits, followed by AstraZeneca's Fasenrahcp.com, and GSK's Nucalahcp.com. The highest proportion of traffic to these sites originated from direct, followed by organic and referral sources.

Teva's Cinqairhcp.com had the highest proportion of traffic from direct searches (81%). Sanofi/Regeneron spent the most on DDA for Dupixenthcp.com at approximately $51,400, followed by Amgen/AstraZeneca's Tezspirehcp.com at approximately $17,100.

Between July 2021 and June 2022, the top 20 social media asthma posts by interaction from pharma were from Sanofi's Facebook accounts, Genentech's Instagram, Regeneron's Instagram, Fasenra's Facebook, and GSK's Instagram. AstraZeneca's Vik Asthma is the only severe asthma app detected from pharma in the US, with an estimated 30,700 downloads in 2021.

Most branded websites in EUCAN are patient-directed and few generated notable traffic between July 2021 and June 2022. Sanofi/Regeneron's Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with about 20,200 and 3,400 visits, respectively.

Between July 2021 and June 2022, eight of the top 20 social media asthma posts by interaction in EUCAN from pharma were from AstraZeneca Espana's Instagram account. No asthma mobile apps were detected from pharma in EUCAN.

Scope

    --  This report assesses key digital marketing metrics of pharma assets in
        severe asthma, including branded websites for patients and healthcare
        professionals (HCPs), mobile apps, and social media accounts.
    --  Metrics include website traffic volume, engagement, and source, digital
        display advertising (DDA), paid search engine optimization (SEO), mobile
        app downloads, and social media post interaction.
    --  Countries include the US, 4EU (Italy, France, Germany, and Spain), the
        UK, and Canada (EUCAN).

Reasons to Buy

    --  Understand the digital marketing competitive landscape in severe asthma,
        with a view of leading patient and HCP branded assets across different
        regions.
    --  See what tactics pharma companies are using to drive traffic to their
        severe asthma branded assets for patient and HCPs, such as DDA and paid
        SEO.
    --  Understand what sources of website traffic are generating the most
        visits to these assets, such as paid SEO, social media, or organic
        searches.
    --  Compare top branded assets for patients by how they address and support
        different patient needs.
    --  See what pharma social media accounts in severe asthma are the most
        active and achieving the most engagement.
    --  See leading mobile app offerings in severe asthma from pharma across
        different regions.

Key Topics Covered:

    --  Executive Summary
    --  US Patient Branded Websites
    --  US HCP Branded Websites
    --  US Digital Display Advertising and Search Engine Optimization
    --  US Mobile Apps and Social Media
    --  EUCAN Branded Websites
    --  EUCAN Mobile Apps and Social Media
    --  Appendix

Companies Mentioned

    --  Sanofi
    --  Regeneron
    --  Genentech
    --  Novartis
    --  GSK
    --  AstraZeneca
    --  Amgen
    --  Teva

For more information about this report visit https://www.researchandmarkets.com/r/dzcu6v

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/severe-asthma-digital-marketing-trends-report-2022-featuring-sanofi-regeneron-genentech-novartis-gsk-astrazeneca-amgen--teva-301683667.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav IAS to Participate at Upcoming Investor Conferences | Dec 3, 2023
Nav Etsy to Participate in Upcoming Investor Conference | Dec 3, 2023
Nav Beat Google's Indexing Errors: Actual SEO Media's Innovative Approach to 'Discovered-Currently Not Indexed' Dilemma | Dec 3, 2023
Nav HigherVisibility Named Top Digital Agency by DesignRush for November 2023 | Dec 3, 2023
Nav Yoast unleashes AI-powered SEO plugin, slashing time investments for crafting vital elements of effective SEO strategies | Dec 3, 2023
Nav "HyBryte(TM) Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery | Dec 3, 2023
Nav Finland Prepaid Card and Digital Wallet Business Opportunities Databook 2023 - Compound Annual Growth of 7.4% with Market Set to Reach US$4.67 Billion by 2027 | Dec 3, 2023
Nav Colling Media Receives Seven 2023 AZIMA TIM Awards Recognizing Top-Performing Campaigns | Dec 3, 2023
Nav Fansearch Launches OnlyFans Search Engine - A Discovery Platform for both OnlyFans Creators and Fans | Dec 3, 2023
Nav 'Cun Chao': The Fiery Soccer Frenzy of Summer in China | Dec 3, 2023
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News